Nimbus Therapeutics
PrivateLast Round
VC Round
Sep 6, 2023
Total Funding Raised
$68.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nimbus Therapeutics is a biotechnology company that develops small molecule compounds aimed at discovering innovative medicines and enhancing drug development for metabolic diseases, cancer, and immune-inflammatory disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nimbus Therapeutics Comparables
Compare Nimbus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Antares Therapeutics | 85% | |
| Insitro | 83% | |
| HotSpot Therapeutics | 83% |
Nimbus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 6, 2023 | ||||
| VC Round | Sep 12, 2022 | ||||
| VC Round | Jul 13, 2021 | ||||
| VC Round | Oct 14, 2020 | ||||
| VC Round | Jun 5, 2018 | ||||
Series B | Mar 18, 2015 |
Key People
Founding team and executive leadership
Nimbus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | VC Round |
| Access Industries | VC Round |
| Bain Capital Life Sciences | VC Round |
| RA Capital Advisors | VC Round |
| RA Capital Management | VC Round |
| SV Health Investors | VC Round |
| GV | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 58% MoM, reaching 12.1K.
- Apr 15, 2026
Presenting new data on SIK2 inhibitor program at IMMUNOLOGY2026.
Nimbus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nimbus Therapeutics's valuation, stock price, and market status.
Is Nimbus Therapeutics a public or private company?
Nimbus Therapeutics is a private company.
What is the current stock price of Nimbus Therapeutics?
Nimbus Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Nimbus Therapeutics worth (valuation)?
Valuation information for Nimbus Therapeutics is not publicly available.
Can I buy Nimbus Therapeutics stock?
Nimbus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nimbus Therapeutics's last funding round?
Nimbus Therapeutics's most recent funding round was VC Round on September 6, 2023.
Who are the main investors in Nimbus Therapeutics?
Key investors in Nimbus Therapeutics include Bain Capital Life Sciences, RA Capital Management, SV Health Investors, GV, Lilly Ventures.
Will Nimbus Therapeutics IPO soon?
No public IPO plans have been announced for Nimbus Therapeutics.
How can I track Nimbus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nimbus Therapeutics's secondary market activity and sign up for updates.